Bruker Corporation and TOFWERK AG announced a strategic partnership for high-speed, ultra-sensitive applied and industrial analytical solutions, in conjunction with a Bruker minority investment in TOFWERK. The partnership provides a basis for technology collaborations to advance instrument ... more
Bruker announces acquisition of a spin-off from Ghent University
Acquisition expands nuclear molecular imaging portfolio
Bruker Corporation announced the acquisition of MOLECUBES NV, a dynamic innovator in benchtop preclinical nuclear molecular imaging (NMI) systems. This acquisition strengthens Bruker’s position as a leading NMI solutions provider in preclinical and translational imaging research.
The combination of Bruker’s preclinical imaging products and global footprint with the modular benchtop CUBES™ systems of MOLECUBES will provide a broader NMI offering to further accelerate worldwide adoption of preclinical NMI in academic medical centers and biopharma companies.
Dr. Wulf I. Jung, President of the Bruker BioSpin Preclinical Imaging Division commented: “Nuclear molecular preclinical and translational imaging research are growing market segments, in which we are already recognized for high-performance simultaneous PET/MR and PET/SPECT/CT instruments, and for our PMOD™ PET data analysis software. The acquisition of MOLECUBES adds scalable benchtop instruments to our portfolio for serving the NMI preclinical research community. The synergies between our and MOLECUBES’ research and development, applications and service teams is expected to benefit our combined NMI customers worldwide.”
Professor Roel Van Holen, CEO of MOLECUBES, added: “The MOLECUBES vision has always centered around making in vivo NMI available to every lab, by developing small footprint imagers without compromising on image quality. The high throughput of our unique scalable technology makes it an excellent tool to speed up drug discovery and translational research. Bruker has the reach to increase access to the CUBES in labs throughout the world, aligning with our joint mission to support the quality and speed of preclinical drug development and fundamental pathobiology research. Our team is looking forward to working within Bruker on research and innovative solutions for our existing and future customers.”
As a fast-growing company founded in 2015 in Ghent, Belgium, MOLECUBES develops and sells high-end PET, SPECT, and CT CUBES™ systems, with a global installated base of more than 70 systems among key opinion leaders. The modular benchtop CUBES complement Bruker’s integrated, floor-standing preclinical small animal imaging systems.
MOLECUBES will remain an innovative and agile operational team within the Bruker BioSpin Preclinical Imaging division, and MOLECUBES customers can continue communications through existing channels. MOLECUBES’ R&D and applications teams will collaborate with Bruker’s preclinical imaging experts to continuously advance NMI technology, software, workflows and applications.
MOLECUBES generated approximately Euro 5 million in FY 2020 revenue. Financial details of the acquisition were not disclosed.
- molecular imaging systems
- in vivo imaging
Bruker Corporation announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, tran ... more
Bruker Corporation announced the acquisition of Prolab Instruments GmbH, a Swiss technology company specialized in low-flow, high precision liquid chromatography technology and systems. Financial terms of the transaction were not disclosed. Mr. Werner Doebelin, the Founder and CEO of Prolab ... more
Diffraction limited high sensitivity (FT-)IR microscopy and imaging at maximum speed ✓ Infrared laser imaging in all measurement modes (ATR, Transmission, Reflectance) ✓ Coherence reduction for artifact free Laser Imaging measurements without sensitivity or speed loss ✓ more
FTIR analysis is an integral part of modern analytics and research. As established and well-proven technology, it provides valuable impulses for industry and science alike more
INVENIO R represents the entry level of Bruker’s R&D FTIR spectrometers for demanding analytical and R&D applications. more
- 1Smartphone-powered microchip for at-home medical diagnostic testing developed
- 2Measuring the ‘wettability’ of graphene and other 2D materials
- 3New method revolutionizes cancer diagnosis
- 4analytica 2022: Analytics that benefit consumer and environmental protection
- 5New technique shows in detail where drug molecules hit their targets in the body
- 6Bruker and TOFWERK Form Strategic Partnership
- 7Researchers demonstrate label-free super-resolution microscopy
- 8A sharper image for proteins
- 9Nanotechnology enables visualization of RNA structures at near-atomic resolution
- 10analytica 2022: New instruments for personalized medicine
- analytica 2022: New instruments for personalized medicine
- Fagron acquires majority share of Fraunhofer IPMS’ spin-off HiperScan
- analytica 2022: Analytics that benefit consumer and environmental protection
- Eppendorf builds new site in Wismar for high-tech polymers used in laboratories
- Olympus Makes it EVIDENT